Clinical Trial Update: Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation [NA]

View source ↗

Summary

This completed clinical trial compares ruxolitinib-based graft-versus-host disease prophylaxis (with a calcineurin inhibitor and methotrexate) against a standar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Calcineurin inhibitor (calcineurin inhibitor)
• METHOTREXATE (METHOTREXATE)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Zhejiang University | Conditions: Graft Versus Host Disease | NA | Status: COMPLETED